Literature DB >> 9741368

Clinical features and prognosis of life time non-smokers with severe alpha 1-antitrypsin deficiency.

N Seersholm1, A Kok-Jensen.   

Abstract

BACKGROUND: The hereditary disorder alpha 1-antitrypsin deficiency is characterised by development of severe emphysema at an early age with smoking being the most significant additional risk factor. The purpose of the present paper was to analyse potential risk factors other than smoking for emphysema and to estimate the prognosis of life time non-smokers.
METHODS: Patients were identified through the files of the Danish alpha 1-antitrypsin deficiency register which contains information on more than 700 persons with the condition. Many of the patients, the non-index cases, were identified from family studies.
RESULTS: There were 75 life time non-smokers with PiZ (27 index cases and 48 non-index cases) aged 20 years or more at entry. Twenty one subjects died during the follow up period. The Standardised Mortality Ratio (SMR) was 3.0 (95% confidence intervals (CI) 1.9 to 4.6). There was no significant difference in SMR between males and females. The SMR was 8.8 (95% CI 5.0 to 14) for the index cases and 0.96 (95% CI 0.3 to 2.3) for the non-index cases based on five deaths. The overall mean % predicted forced expiratory volume in one second (FEV1) at entry was 83% with a significant difference between index cases (54%) and non-index cases (100%) (p < 0.001). The difference in the ratio of FEV1 to forced vital capacity (FVC) was also highly significant with values of 0.57 and 0.79 for index and non-index cases, respectively (p < 0.001). In the non-index group only three had an FEV1% predicted of less than 70%.
CONCLUSIONS: Occupational exposure to airway irritants did not have any significant influence on the development of emphysema. Only a few life time non-smokers develop severe emphysema; most never develop pulmonary symptoms and thus remain undetected unless family members of index cases are screened.

Entities:  

Mesh:

Year:  1998        PMID: 9741368      PMCID: PMC1745189          DOI: 10.1136/thx.53.4.265

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  21 in total

1.  Studies in alpha 1-antitrypsin deficiency.

Authors:  S Eriksson
Journal:  Acta Med Scand Suppl       Date:  1965

Review 2.  The Pi polymorphism: genetic, biochemical, and clinical aspects of human alpha 1-antitrypsin.

Authors:  M K Fagerhol; D W Cox
Journal:  Adv Hum Genet       Date:  1981

3.  Smoking, lung function, and alpha 1-antitrypsin deficiency.

Authors:  E D Janus; N T Phillips; R W Carrell
Journal:  Lancet       Date:  1985-01-19       Impact factor: 79.321

4.  alpha1-Antitrypsin deficiency in nonsmokers.

Authors:  L F Black; F Kueppers
Journal:  Am Rev Respir Dis       Date:  1978-03

5.  Natural history and life expectancy in severe alpha1-antitrypsin deficiency, Pi Z.

Authors:  C Larsson
Journal:  Acta Med Scand       Date:  1978

6.  Effect of age and occupational exposure to airway irritants on lung function in non-smoking individuals with alpha 1-antitrypsin deficiency (PiZZ).

Authors:  E Piitulainen; G Tornling; S Eriksson
Journal:  Thorax       Date:  1997-03       Impact factor: 9.139

7.  Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency of adults with pulmonary symptoms.

Authors:  M L Brantly; L D Paul; B H Miller; R T Falk; M Wu; R G Crystal
Journal:  Am Rev Respir Dis       Date:  1988-08

8.  Alpha 1 antitrypsin deficiency: the clinical and physiological features of pulmonary emphysema in subjects homozygous for Pi type Z. A survey by the British Thoracic Association.

Authors:  M J Tobin; P J Cook; D C Hutchison
Journal:  Br J Dis Chest       Date:  1983-01

Review 9.  Molecular basis of alpha-1-antitrypsin deficiency.

Authors:  M Brantly; T Nukiwa; R G Crystal
Journal:  Am J Med       Date:  1988-06-24       Impact factor: 4.965

10.  The relationship of childhood respiratory illness to adult obstructive airway disease.

Authors:  B Burrows; R J Knudson; M D Lebowitz
Journal:  Am Rev Respir Dis       Date:  1977-05
View more
  12 in total

Review 1.  [Augmentation therapy with human alpha 1-protease inhibitor: whom to treat when?].

Authors:  M Wencker
Journal:  Med Klin (Munich)       Date:  1999-03-15

Review 2.  Alpha1-antitrypsin deficiency. 7: Computed tomographic imaging in alpha1-antitrypsin deficiency.

Authors:  S B Shaker; T Stavngaard; J Stolk; B Stoel; A Dirksen
Journal:  Thorax       Date:  2004-11       Impact factor: 9.139

3.  Predictors of mortality in alpha1-antitrypsin deficiency.

Authors:  P A Dawkins; L J Dowson; P J Guest; R A Stockley
Journal:  Thorax       Date:  2003-12       Impact factor: 9.139

4.  Krüppel-like zinc finger proteins in end-stage COPD lungs with and without severe alpha1-antitrypsin deficiency.

Authors:  A-Rembert Koczulla; Danny Jonigk; Thomas Wolf; Christian Herr; Sarah Noeske; Walter Klepetko; Claus Vogelmeier; Nils von Neuhoff; Johanna Rische; Sabine Wrenger; Heiko Golpon; Robert Voswinckel; Maurizio Luisetti; Ilaria Ferrarotti; Tobias Welte; Sabina Janciauskiene
Journal:  Orphanet J Rare Dis       Date:  2012-05-23       Impact factor: 4.123

5.  The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency.

Authors:  S T Schmid; J Koepke; M Dresel; A Hattesohl; E Frenzel; J Perez; D A Lomas; E Miranda; T Greulich; S Noeske; M Wencker; H Teschler; C Vogelmeier; S Janciauskiene; A R Koczulla
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-09-28

6.  Therapy with plasma purified alpha1-antitrypsin (Prolastin®) induces time-dependent changes in plasma levels of MMP-9 and MPO.

Authors:  Janine Koepke; Marc Dresel; Severin Schmid; Timm Greulich; Björn Beutel; Bernd Schmeck; Claus Franz Vogelmeier; Sabina Janciauskiene; Andreas Rembert Koczulla
Journal:  PLoS One       Date:  2015-01-30       Impact factor: 3.240

Review 7.  Advances in managing COPD related to α1 -antitrypsin deficiency: An under-recognized genetic disorder.

Authors:  Timothy J Craig; Maria Paula Henao
Journal:  Allergy       Date:  2018-07-26       Impact factor: 13.146

8.  Alpha1-antitrypsin deficiency: a clinical-genetic overview.

Authors:  Raja T Abboud; Tanya N Nelson; Benjamin Jung; Andre Mattman
Journal:  Appl Clin Genet       Date:  2011-03-31

Review 9.  Hereditary alpha-1-antitrypsin deficiency and its clinical consequences.

Authors:  Laura Fregonese; Jan Stolk
Journal:  Orphanet J Rare Dis       Date:  2008-06-19       Impact factor: 4.123

Review 10.  Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach.

Authors:  Robert A Stockley; Marc Miravitlles; Claus Vogelmeier
Journal:  Orphanet J Rare Dis       Date:  2013-09-24       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.